MedTrace Logo

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

NCT05765500 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-08-11

No results posted yet for this study

Summary

This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label.

The names of the study drugs involved in this study are:

* Leuprolide (type of ADT)
* Relugolix (type of ADT)

Conditions

Interventions

DRUG

Relugolix

Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.

DRUG

Leuprolide

Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.

Sponsors & Collaborators

Principal Investigators

  • Alicia Morgans, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-12
Primary Completion
2027-07-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05765500 on ClinicalTrials.gov